Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
1. EW reported Q4 sales of $1.39 billion, exceeding estimates. 2. Adjusted EPS came in at 59 cents, beating 55 cents estimate. 3. TAVR sales grew 5.3% YoY to $1.04 billion in Q4. 4. TMTT sales surged 77% YoY, reaching $352 million for the year. 5. Guidance for Q1 2025 indicates stable growth and margin expansion.